Public trial registry of the CCC-Munich

Trial DSMM XVII

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
DSMM XVII
World
Full title
:

Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd ) versus KRd prior to and following Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma and Subsequent Maintenance with Elotuzumab and Lenalidomide versus Single-Agent Lenalidomide Ab Mitte Januar Rekrutierungsstop, Safety-Prüfung 05.10.2021: E-Mail von Dr. Engel (ClinAssess Projektmanagement) Rekrutierungsende

World
NCT number
:
World
Responsible organization
:
3. Med 3. Med Ismaninger Str. 22 81675 München Germany
Indications
Classification Code Description
- Bloodcancer (leukemia, lymphoma)
Trial design
World
Phase
:
III
Status
World
Status
:
Recruitment finished
Votes
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Therapy
World
Therapy line
:
1
World
Therapy
:

Chemo,Zielgerichtet

Participants
Function Prename Surname Organization
World Responsible contact Florian Bassermann 3. Med 3. Med Ismaninger Str. 22 81675 München Germany Magnifier